vimarsana.com
Home
Live Updates
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
– Consistent safety and efficacy profiles across adult and pediatric populations –
Related Keywords
Seattle ,
Washington ,
United States ,
American ,
Sharon Klahre ,
Neil Gallagher ,
American Society Of Hematology Annual Meeting ,
Twitter ,
Syndax Pharmaceuticals ,
Head Of Research ,
Exchange Commission ,
Linkedin ,
European Commission ,
Time Oncology Review Program ,
Prnewswire Syndax Pharmaceuticals ,
American Society Of Pediatric Hematology Oncology ,
Syndax Pharmaceuticals Inc ,
Plenary Session ,
Acute Leukemia ,
Meeting Presentations ,
American Society ,
Hematology Annual ,
Orphan Drug Designation ,
Fast Track ,
Breakthrough Therapy Designation ,
New Drug Application ,
Priority Review ,
Prescription Drug User Fee Act ,
Real Time Oncology Review ,
Rearranged Acute ,
Private Securities Litigation Reform Act ,
Region ,